COMMUNIQUÉS West-GlobeNewswire

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
21/05/2026
- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment [...]
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
21/05/2026
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data SAN DIEGO, Calif., May 21, 2026 (GLOBE [...]
Legend Biotech Announces Presentations at ASCO 2026
21/05/2026
Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data from the CARTITUDE-4 study to highlight a cytogenetic subgroup analysis of [...]
Lunavelle Sleep Patches Claims Evaluated: Most Effective Melatonin-Free Patches for Deeper Rest with Time-Tested Ingredients Proven To Work
21/05/2026
Lunavelle Sleep Patches Research, Ingredients, Side Effects, and Refund Policy Explained: Magnesium Glycinate, L-Theanine, GABA, and Valerian Root Formula San Francisco, CA, May 21, 2026 (GLOBE NEWSWIRE) -- These [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
CONSHOHOCKEN, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21/05/2026
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
21/05/2026
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical [...]
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
21/05/2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant – – Data underscoring unique aspects of [...]
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
21/05/2026
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
21/05/2026
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully [...]
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
21/05/2026
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor [...]
Seven Arrows Recovery Expands Public Education Efforts Around Forward Facing, Nervous System Centered Addiction Treatment
21/05/2026
The Arizona residential treatment center introduces broader awareness of its trauma informed and salutogenic recovery model through Forward Facing Accelerated Recovery™ Elfrida, ARIZONA, May 21, 2026 (GLOBE NEWSWIRE [...]
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
21/05/2026
Cash and cash equivalents totaled €136.1 million as of March 31, 2026 €9.6 million in revenue for the first three months of 2026, from royalties on Ipsen’s sales of Iqirvo® (elafibranor) Positive momentum across all [...]
NMDP Gala in New York City Raises Record-Breaking $660,000 Enabling More Patients to Receive Life-Saving Cell Therapy
21/05/2026
Sanofi Honored with Corporate Leadership Award; Wanda and Robert Zimmer Serve as Honorary Chairs; Sherry Graves Hope Fund for Patient Financial Support Established MINNEAPOLIS, May 21, 2026 (GLOBE NEWSWIRE) -- NMDP℠ [...]
The Joint Corp. Announces Milind Pant Elected as Director
21/05/2026
- Global Executive with Extensive Digital and International Franchise-Led Growth Experience - SCOTTSDALE, Ariz., May 21, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of [...]
BulkGLP Announces Dual-Tier Quality Verification Protocol for Global Supply of Analytical Reference Materials
21/05/2026
Exclusive manufacturing partnership integrates point-of-origin batch testing in Malaysia with strict domestic HPLC and LC-MS verification to ensure uncompromising purity for laboratory reagents. BulkGLP Logo DALLAS, May [...]
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
21/05/2026
TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS Berlin, Germany , May 21, 2026, 18.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company [...]
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026
21/05/2026
TME PHARMA ANNONCE LA CONVOCATION DE L'ASSEMBLÉE GÉNÉRALE ANNUELLE DES ACTIONNAIRES DE 2026 Berlin, Allemagne, le 21 mai 2026, 18 h 00 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), Une société de biotechnologie [...]

Pages